I think that Prurisol is the most likely candidate
Post# of 72440
Brilacidin has the most potential to treat MANY different conditions so it is most likely the most valuable property. (Unless, of course, Kevetrin proves to be a non-toxic cure for cancer, in which case it would be incredibly valuable.) So it would be smart to hold off on a deal for Bril, to maximize the payment to the company and thus to shareholders.
It still amazes me that CTIX/IPIX bought the rights to Brilacidin for 5 million bucks. AXON paid 5 million bucks for the rights to a failed Alzheimer's drug that they are trying to make work (even though it's going down the same failed pathway as all the other Alz drugs) -- and their market cap is 2 Billion with a B.
What's wrong with this picture?